Siltuximab (Sylvant®)
Dokument
Fact Sheet
Spezifizierung
Morbus Castleman
» idiopathic multicentric Morbus Castleman
Stand
Juli 2022
Dies ist die aktuell gültige Version des Dokuments
1Siltuximab, idiopathic multicentric Morbus Castleman
1 N - number of patients2 RR - remission rate, in %7 SAE - serious adverse events, CTCAE grade 3/414 TTF - time to treatment failure15 results for control, results for new therapy16 hazard ratio for new therapy17 n. s. not significant20 n. e.21 durable tumour and symptomatic response for at least 18 weeks22 time to treatment failure, in days
